血塞通片联合胰激肽原酶肠溶片治疗糖尿病周围血管病变的价值评估

The value of treating diabetic peripheral vascular disease with the Xuesaitong tablets and pancreatic kallikrein enteric-coated tablets

目的:探讨血塞通片联合胰激肽原酶肠溶片治疗糖尿病周围血管病变的价值评估。方法:将2016年10月-2017年10月在我院内分泌科治疗的100例糖尿病周围血管病变患者随机分为两组,两组均给予常规控制血糖、营养神经治疗,在此基础上,对照组使用胰激肽原酶肠溶片治疗,观察组使用血塞通片联合胰激肽原酶肠溶片治疗,比较两组患者的临床疗效、踝臂指数变化、症状改善情况。结果:观察组临床总有效率为96%,较对照组的78%明显提升,差异显著(P<0.05);观察组治疗后踝臂指数明显优于对照组,差异有统计学意义(P<0.05);观察组治疗后VAS、TSS、TCSS评分明显低于对照组,差异有统计学意义(P<0.05)。结论:血塞通片联合胰激肽原酶肠溶片治疗糖尿病周围血管病变的临床疗效明显,能有效改善神经功能,促进症状缓解,具有积极的临床意义。

Objective： To evaluate the value of treating diabetic peripheral vascular disease with the Xuesaitong tablets（ 血塞通片） and pancreatic kallikrein enteric-coated tablets. Methods： 100 patients with diabetic peripheral vascular disease in our hospital from October 2016 to October 2017 were randomly divided into two groups. Two groups were given conventional control blood sugar and nutritional therapy. The control group was treated with pancreatic enzyme enteric-coated metformin hydrochloride cream peptides. The observation group received the Xuesaitong tablet and pancreatic kallikrein enteric-coated tablet. The clinical efficacy, ankle brachial index and symptom improvement were compared between two groups. Results： The clinical total effective rate in the observation group was 96%, which was significantly higher than the control group, 78%（P〈0.05）. After treatment, the index of ankle arm was significantly better than that in the control group, and the difference was statistically significant（P〈0.05）. After treatment, the scores of VAS, TSS and TCSS in the observation group were significantly lower than the control group, and the difference was statistically significant（P〈0.05）. Conclusion： The Xuesaitong tablets and pancreatic kallikrein enteric-coated tablets had significant effecton diabetic peripheral vascular disease, could effectively improve the nerve function, promote the relief of symptoms, and had positive clinical significance.